Short answer: In SURMOUNT-ADOLESCENTS, published in JAMA on November 15, 2026, teens aged 12 to 17 with obesity who took weekly tirzepatide (the drug in Zepbound and Mounjaro) had an 18.5% drop in BMI at 72 weeks, vs a 0.5% rise on placebo, in 160 teens. 79.6% of teens on tirzepatide cut their BMI by at least 5%, vs 28.5% on placebo. Zepbound is approved only for adults; its label says safety and effectiveness in children have not been established.
SURMOUNT-ADOLESCENTS tests tirzepatide for obesity in teens, a group where, its authors note, information was limited.Below is how it was run, what it found, what is known about side effects, and where approval stands. We used the published abstract and article details, the ClinicalTrials.gov record and the FDA labels, checked November 18, 2026.
How the trial worked
- Design: phase 3, randomized, double-blind, 72 weeks, at 31 centers in Canada, the Czech Republic, Israel, Italy, Poland and the US, from October 16, 2023, to June 2, 2026 (abstract).
- Who: teens aged 12 to under 18 with obesity, or with overweight plus at least one weight-related health problem. 109 got tirzepatide and 51 got placebo (2:1).
- At the start: average age 14.6, 61.9% girls, average weight 109.7 kg, average BMI 38.6.
- Dose: a weekly injection under the skin, stepped up to the highest dose each teen tolerated: 5, 10 or 15 mg. Both groups also got a healthy lifestyle program.
- Main result: percent change in BMI from the start to week 72.
- Who paid: Eli Lilly, which makes Zepbound and Mounjaro, supplied the drug and was involved in the design, analysis and writing, according to the JAMA article. Several authors work for Lilly.
The ClinicalTrials.gov record (NCT06075667) lists 160 enrolled, primary completion on June 2, 2026, and an estimated study completion of July 2029, so follow-up continues after the 72-week result.
Main results
| Measure at week 72 | Tirzepatide | Placebo | Difference |
|---|---|---|---|
| BMI change | -18.5% | +0.5% | -19.0 points (95% CI -23.9 to -14.1) |
| BMI cut by at least 5% | 79.6% | 28.5% | 51.2 points (95% CI 36.3 to 66.1) |
All 10 key secondary results, including BMI cuts of at least 10%, 15% and 20%, body weight, waist size and physical functioning, favored tirzepatide with statistically significant differences (abstract). The abstract does not give the exact numbers for each one, so we leave them out here.
Side effects
The most common side effects on tirzepatide were stomach and gut problems, mostly mild to moderate, according to the abstract. It does not give rates for specific events or for stopping because of side effects.
In adults, the Zepbound label lists nausea, diarrhea, vomiting and constipation among the most common side effects, and says most nausea, vomiting and diarrhea happened during dose increases. Our page on side effects week by week has the adult label rates.
How it compares with Wegovy in teens
Wegovy is the drug in this class approved for weight in teens 12 and older. In its 68-week teen trial of 201 patients, BMI fell 16.1% on Wegovy 2.4 mg vs a 0.6% rise on placebo, per the Wegovy label (section 14.3, Table 18). SURMOUNT-ADOLESCENTS found -18.5% vs +0.5% at 72 weeks. These were separate trials with different teens, lengths and doses, so they are not a head-to-head comparison.
A day later, a semaglutide trial in children aged 6 to 11 was published. See our breakdown of the Wegovy STEP Young trial.
Where approval stands
- The current Zepbound label (DailyMed version of September 2, 2026) covers weight reduction and sleep apnea in adults only, and says safety and effectiveness in children have not been established.
- Mounjaro, the same drug, is approved for type 2 diabetes in children 10 and older. That is a blood sugar use, not a weight-loss approval.
- A published trial does not mean approval. A teen weight indication for Zepbound would need an FDA review.
What this means for you
For families, this trial adds a second strong data set for teen obesity treatment, alongside the approved Wegovy. It is not a treatment plan: Zepbound is not approved for teens, and the trial ran with a lifestyle program and close follow-up. Questions to bring to a doctor include side effects, growth, and what happens if the drug is stopped; in adults, weight tends to return, as our page on stopping and weight regain shows. Our Zepbound label summary and how long tirzepatide stays in your system cover the adult label.
Frequently asked questions
What is SURMOUNT-ADOLESCENTS?+
How much did BMI drop on tirzepatide in teens?+
Is Zepbound approved for teenagers?+
What doses were used in SURMOUNT-ADOLESCENTS?+
What side effects did teens have on tirzepatide?+
Related reading
- Zepbound label summary
- Mounjaro label summary
- Wegovy STEP Young trial in children 6 to 11 (2026)
- How long tirzepatide stays in your system
- Ozempic vs Mounjaro compared
- What happens when you stop: the trial data
Questions about the app? See the help center or join the Dose Track community.
Sources
Every fact in this article comes from one of these sources, checked on November 18, 2026. This article is for education. It is not medical advice, and nothing here is a dose recommendation.
- Kelly AS, et al. Tirzepatide in adolescents with obesity: the SURMOUNT-ADOLESCENTS randomized clinical trial. JAMA. Published online November 15, 2026. doi:10.1001/jama.2026.23420. PMID 43035096. PubMed · JAMA
- ClinicalTrials.gov. NCT06075667: Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS). clinicaltrials.gov
- Zepbound (tirzepatide) label, Eli Lilly, DailyMed version of September 2, 2026: sections 1, 6.1 and 8.4. DailyMed
- Mounjaro (tirzepatide) label, Eli Lilly, DailyMed version of September 2, 2026: section 1. DailyMed
- Wegovy (semaglutide) label, Novo Nordisk, DailyMed version of June 30, 2026: section 14.3. DailyMed
- Jastreboff AM, et al. Semaglutide for the treatment of obesity in children 6 to <12 years of age. N Engl J Med. Published online November 16, 2026. PMID 43037562. PubMed